Sorry, this is not a mid-term 10-bagger. Nothing even approaching it. Remember that the market cap of this company is now 300 million. 300 million!
There is no way that Ropren sales can begin to justify a valuation like that. FDA approval is still years away, with a full Phase III trial to launch, or possible partnering (and associated revenue dilution).
Anyway, enjoy your holiday in Honkers. What a great spot. I hope you have some Solagran bubble bath handy to soothe your bottom line. I am appropriately jealous.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
0.005(3.03%) |
Mkt cap ! $9.857M | |||
| Open | High | Low | Value | Volume |
| 16.5¢ | 17.0¢ | 16.5¢ | $22.91K | 138.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 108382 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 1245 | 1 |
View Market Depth
| Last trade - 16.10pm 10/07/2025 (20 minute delay) ? |
| SLA (ASX) Chart |